Barclays lowered the firm’s price target on DexCom (DXCM) to $67 from $72 and keeps an Underweight rating on the shares. The firm remains concerned over rising competition following the company’s Q1 beat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Buy Rating Reaffirmed on Dexcom as Margin Strength and Global Patient Growth Offset U.S. CGM Concerns; Price Target Reset to $75
- Closing Bell Movers: Apple higher after stronger than expected guidance
- DexCom affirms FY26 revenue $5.16B-$5.25B, consensus $5.23B
- DexCom reports Q1 EPS 56c, consensus 47c
- Notable companies reporting after market close